Non-steroid agents for idiopathic pulmonary fibrosis (Intervention Review)
Spagnolo, P and Del Giovane, C and Luppi, F and Cerri, S and Balduzzi, S and Walters, EH and D'Amico, R and Richeldi, L, Non-steroid agents for idiopathic pulmonary fibrosis (Intervention Review), Cochrane Database of Systematic Reviews, 2010, (9) EJ ISSN 1469-493X (2010) [Refereed Article]
Idiopathic pulmonary fibrosis is a chronic progressive lung disease with poor outcome and no effective treatment to date. This is an
update of a Cochrane Review first published in 2003.
To assess the efficacy of non-steroid agents in adults with idiopathic pulmonary fibrosis.
We searched the Cochrane Airways Group Register (30March 2010), the Cochrane Central Register of Controlled Trials (CENTRAL)
(The Cochrane Library, Issue 1, 2010), Ovid MEDLINE to March week 5, 2010, EMBASE to week 13, 2010 and PubMed to April
2010, with additional handsearching, including abstracts of international conferences. We also contacted pharmaceutical companies
and researchers in the field.
Randomised studies comparing non-steroid drugs with placebo or steroids in adults with idiopathic pulmonary fibrosis.
Data collection and analysis
Two authors independently assessed trial quality, extracted data and assessed risk of bias. We contacted pharmaceutical companies to
obtain missing information, if any. We combined survival outcomes using Peto odds ratios or hazard ratios (HR).
Fifteen trials involving 10 different drugs were included. Two trials enrolling 1156 patients compared interferon gamma-1beta with
placebo: interferon gamma-1beta did not significantly improve survival (HR 0.88, 95%CI 0.47 to 1.64; P = 0.68). Four trials involving
1155 patients compared pirfenidone with placebo. Three trials, conducted in 1046 patients, provided data on progression-free survival:
pirfenidone significantly reduced the risk of disease progression by 30% (HR 0.70, 95% CI 0.56 to 0.88, P = 0.002). Data on the
effect of pirfenidone on pulmonary function could only be assessed for two studies analysing 314 patients. Forced vital capacity or vital
capacity was significantly improved by pirfenidone (mean difference 0.08 L, 95% CI 0.03 to 0.13, P = 0.0006).